Cargando…
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
The effects of a combination of aminoglutethimide (AG) 1,000 mg daily and 4-hydroxy-androstenedione (4OHA) 500 mg i.m. weekly on peripheral aromatase activity as measured by in vivo radioisotopic tracer methodology and serum oestrogen suppression were investigated in ten post-menopausal women with a...
Autores principales: | MacNeill, F. A., Jacobs, S., Lønning, P. E., Powles, T. J., Dowsett, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969459/ https://www.ncbi.nlm.nih.gov/pubmed/8198987 |
Ejemplares similares
-
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
por: MacNeill, F. A., et al.
Publicado: (1992) -
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992) -
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
por: Johannessen, D. C., et al.
Publicado: (1993) -
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1991) -
Role of aminoglutethimide in male breast cancer.
por: Harris, A. L., et al.
Publicado: (1986)